// App-Quantinova.ai

56 : A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Researchers

Presenter

  • Ian W. Flinn

Principal Investigators

  • Laurie H. Sehn

  • Robert Kahn

  • Dan Lu

  • Zheng Su

  • Yu-Waye Chu

  • Sarit E. Assouline

  • Manish Patel

  • Randeep Sangha

  • Myron S. Czuczman

  • Gilles Andre Salles

  • Franck Morschhauser

  • Ranjana Advani

  • Oliver W. Press

  • William Ho

Medical Centers

  • Jewish General Hospital, Montreal, QC, Canada

  • Hopital Claude Huriez, Lille, France

  • Cross Cancer Institute, alberta, AB, Canada

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • France

  • Canada

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Diffuse large B-cell lymphoma

  • Non-Hodgkin's Lymphoma

  • Peripheral neuropathy

  • B cell lymphomas

  • Arrhythmia

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Congestive heart failure

  • Hyperglycemia

  • Constipation

  • Non‐Hodgkin Lymphoma

  • Neutropenia

  • Lymphomas

  • Anemia

Biomarkers

  • Breakpoint Cluster Region

  • Apparent diffusion coefficient

Drug/Treatment

  • monomethyl auristatin E

  • Rituximab

  • DCDT2980S

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved